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Abstract
Calpain, a calcium-dependent cysteine protease, is reportedly involved in the pathophysiology of autoimmune diseases such
as rheumatoid arthritis (RA). In addition, autoantibodies against calpastatin, a natural and specific inhibitor of calpain, are
widely observed in RA. We previously reported that E-64-d, a membrane-permeable cysteine protease inhibitor, is effective in
treating experimental arthritis. However, the exact role of the calpastatin-calpain balance in primary inflammatory cells
remains unclear. Here we investigated the effect of calpain-specific inhibition by overexpressing a minimal functional domain
of calpastatin in primary helper T (Th) cells, primary fibroblasts from RA patients, and fibroblast cell lines. We found that the
calpastatin-calpain balance varied during Th1, Th2, and Th17 development, and that overexpression of a minimal domain of
calpastatin (by retroviral gene transduction) or the inhibition of calpain by E-64-d suppressed the production of IL-6 and IL-17
by Th cells and the production of IL-6 by fibroblasts. These suppressions were associated with reductions in RORct expression
and STAT3 phosphorylation. Furthermore, inhibiting calpain by silencing its small regulatory subunit (CPNS) suppressed Th17
development. We also confirmed that overexpressing a minimal domain of calpastatin suppressed IL-6 by reducing NF-kB
signaling via the stabilization of IkBa, without affecting the upstream signal. Moreover, our findings indicated that calpastatin
overexpressionsuppressed IL-17production byThcellsbyup-regulating the STAT5signal. Finally, overexpression ofaminimal
domain of calpastatin suppressed IL-6 production efficiently in primary fibroblasts derived from the RA synovium. These
findings suggest that inhibiting calpain by overexpressing a minimal domain of calpastatin could coordinately suppress
proinflammatory activities, not only those of Th cells but also of synovial fibroblasts. Thus, this strategy may prove viable as a
candidate treatment for inflammatory diseases such as RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by symmetric polyarthritis, accompanied by joint
destruction, and is widely regarded as a systemic autoimmune
disease. Although the pathogenesis of RA is not yet fully
understood, several studies indicate that helper T (Th) cells
assume an important role. Naı ¨ve CD4
+ T cells differentiate into
distinct types of Th cells: IFN-c-producing Th1 cells, IL-4-
producing Th2 cells, and the recently defined IL-17-producing
Th17 cells [1,2,3]. IL-12, STAT4, and T-cell-specific T-box
transcription factor (T-bet) signals are known to be important for
Th1 development, as are IL-4, STAT6, and GATA binding
protein 3 (GATA-3) signals for Th2 development [4,5,6], and IL-
1b, TGF-b, IL-6, IL-23, STAT3, and retinoic acid-related orphan
receptor gamma t (RORct) signals for Th17 development
[1,2,7,8,9,10,11]. Although Th1 cells were formerly considered
the main effector cells for the pathogenesis of autoimmune
arthritis, we now know that Th17 cells play an essential role in
autoimmune arthritis in mice. For example, in collagen-induced
arthritis (CIA) model mice, systemic or local IL-17 gene transfer
aggravates CIA and enhances joint destruction, whereas the
administration of an IL-17-blocking antibody ameliorates CIA,
even after disease onset [12,13]. However, whether this finding
can be applied to human RA remains controversial. Two
independent groups including ours have reported that Th1 cells
are dominant while Th17 cells are scarce in the synovial tissues
and fluids of RA patients [14,15].
On the other hand, various autoantibodies such as rheumatoid
factor (RF), anti- citrullinated protein [16], anti-type II collagen
(CII) [17], and anti-glucose-6-phosphate isomerase (GPI) antibody
[18] have been proposed to have pathogenic roles in RA. In
particular, we and others have documented the presence of anti-
calpastatin (a natural specific inhibitor of calpain) antibodies in RA
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calpastatin antibodies for diagnosing RA are 83% and 96%,
respectively [22]. Positivity for these antibodies correlates with
serological markers of the disease activity [23,24], and their
detection is applicable to the diagnosis of early RA [25].
Furthermore, these anti-calpastatin antibodies are known to
inhibit the function of calpastatin [19,21]. Calpain, a calcium-
dependent cysteine protease, is thought to modulate various
intracellular signaling pathways [26], and may contribute to the
pathogenesis of RA. For example, calpain is reportedly up-
regulated in the synovial tissue of RA and CIA mice [27,28], and
has been shown to degrade the matrix component of articular
cartilage [29]. One report demonstrated the successful treatment
of CIA with calpain inhibitor I [30]. There are reports that calpain
is involved in LFA-1-mediated T-cell adhesion [31], as well as T-
cell proliferation via a-actinin-modification [32]. Thus, it is
conceivable that excess calpain in the joints of RA patients whose
calpastatin activity is inhibited by the presence of anti-calpastatin
antibodies could contribute to the pathophysiology of RA. In this
regard, we also reported that E-64-d, a membrane-permeable
calpain inhibitor, ameliorates anti-collagen antibody-induced
arthritis (CAIA), another animal model of RA [33]. Taken
together, these results suggest that an insufficiency of calpastatin or
an overabundance of calpain contributes to the pathogenesis of
inflammatory diseases such as RA.
In this study, we found that the calpastatin-calpain balance
modulated the fate of Th-cell development, and that inhibiting
calpain by overexpressing a minimal functional domain of
calpastatin suppressed IL-6 production and Th17 development
in primary Th cells, and the production of IL-6 by primary human
fibroblasts from the RA synovium. We also examined the
mechanisms underlying these effects.
Materials and Methods
Mice and reagents
BALB/c mice (6–10-weeks old) were purchased from Charles
River Laboratories. The mice were maintained in our animal
facility under specific pathogen-free conditions and treated in
accordance with the guidelines for animal care at Kyoto University.
All animal procedures were approved by the ethics committees of
Kyoto University (MedKyo 10142). Calpastatin cDNA was
obtained from a lgt11 cDNA library [19]. Calpain cDNA was
purchased from Open Biosystems, and E-64-d was from Peptide
Institute (Japan). Recombinant human IL-2, and murine IL-4, IL-6,
and IL-12 were purchased from PeproTech Inc.; human TGF-b
was from R&D Systems. Monoclonal antibodies to murine CD3
(2C11) and CD28 (37.51) were purchased from eBioscience and BD
Biosciences,respectively.Anti-IL-4antibody(11B11)waspurchased
from BioLegend Inc., and anti-IFN-c antibody (XMG1.2) from BD
Biosciences. Phoenix 293T cells and NIH-3T3 cells (ATCC) were
maintained in DMEM with 10% FCS, 10 U/ml penicillin, 10 mg/
ml streptomycin, 50 mM 2-ME, and 20 mM HEPES. CD4
+ T cells
from mice were maintained in RPMI1640 using the supplements
listed above. All other reagents, unless stated otherwise, were
purchased from Invitrogen Corp.
Cells and cultures
Naı ¨ve CD4
+ T cells derived from murine splenocytes were
purified by negative selection using the Mouse CD4
+ T cell
Isolation Kit, followed by positive selection using anti-mouse
CD62L MicroBeads (Miltenyi Biotec). Naı ¨ve CD4
+ T cells were
stimulated with 4 mg/ml plate-bound anti-CD3 monoclonal
antibodies and 2 mg/ml soluble anti-CD28 monoclonal antibodies
(eBioscience) under neutral (no cytokine) conditions, or Th1 (IL-
12, 5 ng/ml)- or Th2 (IL-4, 20 ng/ml)-promoting conditions, then
expanded with 10 U/ml human IL-2. For the Th17-promoting
condition, naı ¨ve CD4
+ T cells were stimulated with 1 mg/ml plate-
bound anti-CD3 monoclonal antibodies and 0.5 mg/ml soluble
anti-CD28 monoclonal antibodies in the presence of 20 ng/ml IL-
6, 5 ng/ml TGF-b, and 20 ng/ml anti-IFN-c antibody.
Human synovial tissues were obtained from RA patients
undergoing joint replacement or the subcutaneous puncture of
knee joints. Synovial tissue was dissected into small pieces with
scissors, and digested with Liberase TM Research Grade (Roche
Diagnostics). Synovial cells were then seeded into dishes, and
infected with retrovirus several days later. All human materials
were used under the approval of the Ethics Committee of Kyoto
University, and written informed consent was obtained from all
patients (E458).
Plasmid construction and retroviral transduction
The retrovirus vector (pBMN-IRES-EGFP) was kindly provided
by Dr. G. Nolan (Stanford University). The cDNAs for full-length
calpastatin or calpain were inserted into the pBMN-IRES-EGFP
vector using the EcoRI and EcoRI/NotI sites, respectively. The
minimal functional domains of calpastatin were cloned by PCR
using the following primers: sense primer 59-GAA TTC AGA TCT
GCC ACC ATG GAT GCT GCT TTG GAT-39, for domains
IABC and IAB, anti-sense primer, 59-GAA TTC GCG GCC GCC
TAG GTG AAG TCA GAT GAC AA-39, for domain IABC, 59-
GAA TTC GCG GCC GCC TAG GGT TTA GCC AAT AGT
TC-39 for domain IAB, sense primer 59-GAA TTC AGA TCT
GCCACCATGGACCTCGATGATGCCTTG-39 fordomain
IVABC and IVAB and anti-sense primer 59- GAA TTC GCG
GCC GCC TAC AGA TCT CCT GAG AGA GCA TC-39 for
domain IVABC, 59- GAA TTC GCG GCC GCC TAA TTATCA
TCC AGG AGA TG-39 for domain IVAB. The PCR products
were cloned into a pCR4 Blunt-TOPO vector (Invitrogen) followed
by bidirectional sequencing, then subcloned into the pBMN-IRES-
EGFP vectorusing the EcoRIandNotIsites.Retroviral transfection
and infections were performed as previously described [5]. Naı ¨ve
CD4
+ T cells or NIH-3T3 cells were infected with collected viral
supernatants containing 2 mg/ml polybrene (Sigma-Aldrich).
PKH-26 labeling and ATP measurement to assay cell
proliferation
To analyze the effect of retrovirus infection on the proliferation
of Th cells, Th cells were stained with the dye PKH-26 (Sigma-
Aldrich, St. Louis, MO), according to the manufacturer’s
instructions, then stimulated with anti-CD3/28 monoclonal
antibodies. The fluorescence intensities of the infected cells were
then analyzed by FACS. To analyze the effect of retroviral
infection on the proliferation of primary fibroblasts from RA
patients, the GFP-positive cells were sorted and plated into 96-well
plates at 1000 cells/well. Forty-eight and 72 hours after plating,
ATP was measured with a CellTiter-GloH Assay kit according to
the manufacturer’s instructions (Promega Corporation).
Calpain activity assay and ELISAs
Calpain activity was assayed as previously described [19].
ELISAs for IL-6 and IL-17 using Ready-set-Go! (eBioscience),
according to the manufacturers’ protocols.
Intracellular cytokine and IkBa staining
Intracellular cytokine staining was performed as previously
described [5]. APC-conjugated anti-mouse IFN-c (XMG1.2), PE-
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(MP5-20F3), and anti-mouse IL-17 (TC11-18H10) were used to
detect these cytokines in cells. As negative controls, APC- or PE-
conjugated isotype-matched monoclonal antibodies were used.
Intracellular staining of IkBa was performed using an anti-IkBa
antibody (sc-847) and APC-conjugated goat anti-rabbit IgG F(ab)
2
antibody (sc-3846), both from Santa Cruz Biotechnology,
according to the recommended protocol of Santa Cruz Biotech-
nology. The analysis was performed on a FACS Calibur with Cell
Quest software (BD Biosciences). All reagents were purchased
from BD Biosciences unless otherwise stated.
Western blotting and densitometry
Protein extraction and Western blot analysis were performed by
standard methods as previously described [34]. Anti-m-calpain
large subunit specific antibody (#2556), anti-phosphorylated
STAT5 antibody (#9359), and the NF-kB Pathway Sampler Kit
(#9936) were purchased from Cell Signaling Technology. Anti-
calpastatin antibody (sc-20779), anti-actin antibody (sc-1616), anti-
phosphorylated STAT3 antibody (sc-8059), anti-STAT3 antibody
(sc-482), anti-STAT5 antibody (sc-835), and anti-NF-kB p65
antibody (sc-109) were purchased from Santa Cruz Biotechnology.
Anti-calpain small subunit (CPNS) antibody (826-M01) was
obtained from Abnova Corp. To analyze phosphorylated STAT3
and STAT5 in Th cells, the cells were incubated with X-VIVO
TM
20 (without FCS, Lonza Walkersville, Inc.) for the last six hours
and then lysed. After SDS-PAGE and electrotransfer to a
membrane, the blotted membranes were blocked with TBS
containing 5% non-fat milk and 0.05% Tween-20, probed with
the indicated antibody, and developed using the Supersignal
Chemiluminescence kit (Pierce Chemical Co.). The chemilumi-
nescence signals were detected with BioMax Light film (Kodak) or
an ImageQuant LAS 4000 mini (GE Healthcare). After stripping,
the membranes were reprobed. The band densities on western
blots were scanned and measured using NIH Image.
Electrophoresis mobility shift assay
Nuclear extracts were prepared using NE-PER nuclear and
cytoplasmic extraction reagents (Thermo Fisher Scientific Inc.).
Electrophoresis mobility shift assays (EMSAs) were performed by
incubating nuclear extracts and biotin-labeled double strand
probes in a binding buffer (10 mM Tris, 50 mM KCl, 1 mM
DTT, pH 7.5) at room temperature for 20 min. For the NF-kB-
binding motif, the sequences of the oligonucleotides used for
EMSA were: sense, 5-biotin/AGT TGA GGG GAC TTT CCC
AGG-3; and anti-sense, 5-biotin/CCT GGG AAA GTC CCC
TCA ACT-3 (Invitrogen). Probes labeled at the 59 end with biotin
and non-labeled probes were both prepared by annealing these
two oligonucleotides. For super-shift experiments, the binding
reactions were conducted in the presence of specific antibodies to
p65 protein (sc-109, Santa Cruz). The protein–DNA complexes
were subjected to electrophoresis on 5% polyacrylamide gels in
0.56TBE and transferred onto a positive-charged nylon mem-
brane (Hybond N+, GE Healthcare). The UV cross-linked
membrane was then blocked and incubated with horseradish
peroxidase-conjugated streptavidin, and visualized with a Light-
shift chemiluminescent EMSA kit (Pierce Chemical Co.) using an
ImageQuant LAS 4000 mini (GE Healthcare). Band densities
were measured using NIH Image.
RNA interference (RNAi)
Predesigned Stealth Select siRNAs against CPNS, and negative
controls (Medium GC SUplex #2) were purchased from
Invitrogen. Transfection with siRNA was carried out using
Lipofectamine RNAiMAX (Invitrogen) according to the manu-
facturer’s instructions.
RNA isolation, cDNA synthesis, and quantitative real-time
PCR
RNA was isolated using ISOGEN (Nippon Gene). First-strand
cDNA was synthesized with reverse transcriptase (Superscript III,
Invitrogen) and random primers in 20 ml of the reaction buffer.
Synthesized first-strand cDNA was amplified by quantitative real-
time PCR performed on an ABI Prism 7500 Sequence Detection
System (Applied Biosystems), with qPCR
TM Mastermix Plus for
SYBR Green I (Eurogentech) for T-bet and RORct, and
qPCR
TM Mastermix Plus (Eurogentech) for hypoxanthine-gua-
nine phosphoribosyltransferase (HPRT) and 0.4 mM gene-specific
primers. The primer pairs for T-bet and HPRT used in the
quantitative real-time PCR were described before [5]. The primer
pair for RORct was: sense primer, 59-TAC CTT GGC CAA
AAC AGA GG-39; anti sense primer, 59-GAT GCC TGG TTT
CCT CAA AA-39.
Statistical analysis
The Mann-Whitney U-test was performed for two-group
comparisons. Dunnett’s (one-way ANOVA) or Steel’s (Kruskal
Wallis test) test was performed for multiple group comparisons
against a reference group. P values,0.05 were considered
statistically significant. Error bars in all figures indicate standard
errors of mean (SEM).
Results
The expressions of calpastatin and calpain are differently
regulated during Th1, Th2, and Th17 development
To investigate the roles of calpain and calpastatin in Th cell
development, we first examined their expressions over time during
Th1, Th2, and Th17 development. Anti-CD3/28 monoclonal
antibodies-stimulated naı ¨ve CD4
+ T cells were cultured under
neutral, Th1-, Th2-, or Th17-promoting conditions, and the
lysates were subjected to western blot analysis. As shown in
figure 1A–1B, the expression level of calpastatin consistently
declined during Th1 development, and the calpain/calpastatin
ratio in these cells eventually reached its maximum level for all the
Th conditions. In contrast, the expression level of calpastatin
gradually recovered during Th2 development after a transient
decrease on day 2. The kinetics of calpain expression during the
Th1, Th2, and Th17 developments were similar, but the degree of
the transient decline was only modest in the Th17 conditions.
Developing Th17 cells showed the smallest changes in calpain and
calpastatin expression levels. In addition, intermediate trends of
these proteins were observed in neutral conditions (Figure S1).
These data suggested that the expressions of calpastatin and
calpain were differently regulated during Th1, Th2, and Th17
development, and might modify the fate of Th development.
E-64-d selectively inhibits Th17 development
We next studied the effect of E-64-d, a membrane-permeable
calpain inhibitor, on the cytokine production in Th cells, and
found that it had an effect in Th17 cells. Naı ¨ve CD4
+ T cells were
cultured with or without E-64-d under neutral or Th17 conditions,
and restimulated with PMA/ionomycin for intracellular cytokine
staining. E-64-d significantly suppressed the emergence of IL-17-
positive cells under Th17 conditions in a dose-dependent manner
(Figure 1C–1D). This suppression was associated with reductions
in RORct expression and STAT3 phosphorylation (Figure 1E–
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was also observed under neutral conditions, it was modest and not
evident under Th17 conditions (Figure 1C). These data suggested
that the calpain inhibitor selectively suppresses Th17 develop-
ment.
Retroviral overexpression of calpastatin minimum
functional domains
We found that the expression of calpastatin and calpain was
differently regulated during Th1, Th2, or Th17 development, and
that E-64-d suppressed Th17 development. However, since E-64-d
inhibits not only calpain but also cathepsin [35,36], it was possible
that E-64-d’s effect on Th17 development was a result of cathepsin
blockage. Therefore, we constructed a retrovirus system to
overexpress calpastatin, the specific inhibitor of calpain. As shown
in figure 2A, we generated mock-, calpastatin-, and calpain-
integrated retroviruses with a GFP reporter (mock-, calpastatin-,
and calpain-GRV). Anti-CD3/28 monoclonal antibodies stimu-
lated naı ¨ve CD4
+ T cells were cultured under neutral conditions
and infected with these retroviruses. The efficiencies of infection
were determined from the GFP expression using flow cytometry.
However, compared with the mock-GRV-infected cells, the
expression of full-length (FL) calpastatin-GRV in infected CD4
+
T cells was not maintained, and the positive cells had almost
disappeared by day 7 after infection (Figure S2). As this might
have been owing to the length and/or sequence of the calpastatin
cDNA, we next cloned minimum functional domains of
calpastatin by PCR.
As shown in figure 2A, the calpastatin cDNA contains four
homologous functional domains (I to IV), and domains I and IV
have a higher calpain-inhibiting activity than domains II and III
[37]. Each inhibitory domain has three sub-domains A, B, and C:
sub-domains A and C bind to calpain, and subdomain B is crucial
for calpastatin’s inhibitory activity. Therefore, we cloned domains
I and IV, as just subdomains A and B (CS-dIAB, CS-dIVAB) or all
three subdomains (CS-dIABC, CS-dIVABC). These retrovirally
overexpressed minimum domains of calpastatin showed much
better stability in infected cells than the full-length sequence
(Figure S2).
Overexpression of calpastatin minimum functional
domains suppresses the IL-6 production from fibroblasts
To confirm the overexpression of calpastatin and calpain
proteins, we transfected the retroviruses into Phoenix 293T cells,
and then subjected the lysates of these cells to western blot analysis.
We detected the expected sizes of calpastatins and calpain proteins
Figure 1. Calpastatin and calpain expressions and the effect of E-64-d on Th cell development. (A) Naı ¨ve CD4
+ T cells were cultured
under Th1-, Th2-, or Th17-promoting conditions, and the lysates were subjected to western blot analysis with the indicated antibodies. Data are
representative of four independent experiments. (B) Band densities from the four independent experiments described in panel A were measured and
normalized against the density of actin, and are depicted as the percent change from the value on day 0. (C) Naı ¨ve CD4
+ T cells were maintained with
the indicated concentrations of E-64-d under neutral or Th17-promoting conditions. On day 4 (Th17 condition) or day 6 (neutral condition), the cells
were restimulated with PMA/ionomycin for 4 hours and subjected to ICS. Similar results were obtained in four independent experiments. (D)
Statistical analysis of the IL-17 positive rates in panel C under Th17 conditions. *p,0.05 vs. absence of E-64-d (DMSO only, n=4). (E) Naı ¨ve CD4
+ T cells
were maintained with the indicated concentrations of E-64-d under Th17-inducing conditions. On day 3, total RNA was extracted and subjected to
quantitative RT-PCR analysis for RORct. Expression levels were normalized to HPRT. Data depict the average+SE of the percent change from the value
in the absence of E-64-d (DMSO only, n=6). *p,0.05 vs. absence of E-64-d. (F) Th17 cells were cultured with the indicated concentrations of E-64-d.
On day 3, the cells were washed and maintained with X-VIVO
TM 20 (without FCS), and then lysed and subjected to western blot using the indicated
antibodies on day 4. Similar results were obtained in four independent experiments. Numbers below the blots are the average relative density of
pSTAT3 to actin.
doi:10.1371/journal.pone.0027020.g001
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functional domains of calpastatin with different sets of subdomains
and calpain at the protein level, a casein-based calpain activity
assay was performed using lysates from calpastatin- or calpain-
overexpressing NIH-3T3 cells, as described previously [19], and
the calpain inhibitor function was confirmed for all these
constructs (data not shown).
As we previously found that E-64-d suppresses IL-6 production
in a fibroblast-like synovial cell line [33], we examined the
biological function of the calpastatins and calpain by the IL-6
production using NIH-3T3 cells. Control cells and calpastatin- or
calpain-overexpressing NIH-3T3 cells (infection efficiencies were
.95%) were stimulated with LPS (Figure 2C) or IL-17 (Figure 2D),
and the IL-6 concentration in the culture supernatants was
measured by ELISA. The IL-6 induction was significantly
suppressed in cells overexpressing all forms of calpastatin similarly,
whereas the calpain-overexpressing cells produced more IL-6 than
mock-infected cells (Figure 2C–2D). These results suggested that
the target molecule of calpain and calpastatin might lie in the
common signal pathway of IL-6 gene expression such as the NF-
kB signal rather than in the receptor level. In addition, in the
absence of LPS stimulation, the constitutive phosphorylation of
STAT3, which is an important effector of IL-6 signal transduction,
was also suppressed in calpastatin-overexpressing NIH-3T3 cells
as a result of the IL-6 suppression (Figure 2E). On the other hand,
no upregulation of phosphorylated STAT3 was observed in
calpain-overexpressing NIH-3T3 cells, probably because of the
absence of LPS stimulation.
Because of its stability and strong biological effect, we used the
dIV-ABC construct of calpastatin in further experiments (desig-
nated just as CS-dIV).
Production of IL-17 and IL-6 was suppressed in
calpastatin-overexpressing CD4
+ T cells
We next investigated the effect of calpastatin and calpain
overexpression on cytokine production in Th cells. Calpastatin- or
calpain-overexpressing CD4
+ T cells were cultured under neutral,
Th1-, Th2-, or Th17-promoting conditions, and cytokine
production was analyzed by intracellular cytokine staining.
Compared with mock-infected or calpain-overexpressing Th cells,
those overexpressing CS-dIV contained fewer IL-6- and IL-17-
positive cells under Th2 and Th17 conditions, respectively
(Figure 3A–3B). Furthermore, CS-dIV overexpression completely
blocked the emergence of IL-17-positive Th cells under neutral
Figure 2. Retroviral expressions of calpastatin, calpastatin domains, and calpain and effect on IL-6 production from fibroblasts. (A)
Retroviral construction and scheme of the domain structure of calpastatin. Domains I and IV are abbreviated as dI and dIV, respectively. (B)
Calpastatin- or calpain-GRV was transfected into phoenix 293T cells by the calcium phosphate method. Three days later, the lysates of these cells
were subjected to western blot analysis. The blots were probed with anti-calpastatin and anti-calpain antibodies. (C–D) Control cells, or calpastatin- or
calpain-overexpressing NIH-3T3 cells (5x10
5 cells/ml) were cultured with 1 mg/ml LPS (C) or 10 ng/ml IL-17 (D) for 24 hours. The culture supernatants
were collected and IL-6 concentrations were measured by ELISA. Left panel of (C) shows mock vs. calpastatins (Dunnett’s test, n=5), and right panel
shows mock vs. calpain (Steel’s test, n=5). Panel D shows the results of three independent experiments (Steel’s test). *P,0.05 and **p,0.01 vs. mock.
FL, full-length. (E) Control cells, calpastatin-, and calpain-overexpressing NIH-3T3 cells (infection efficiencies were .95%) were maintained without
stimulation, then lysed and subjected to western blot analysis with the indicated antibodies. Similar results were obtained in three independent
experiments. Numbers below the blots are the average relative densities of pSTAT3 to actin.
doi:10.1371/journal.pone.0027020.g002
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CD4
+ T cells showed little change with regard to the production of
IFN-c and IL-4. We also checked the effect of CS-dIV
overexpression on cell proliferation using PKH26 labeling
together with GFP expression, and found no difference in the
cell-division rates between mock- and CS-dIV-infected cells
(Figure 3D). These data suggested that the overexpression of
CS-dIV suppressed IL-17 and IL-6 production without causing
cytotoxic effects.
To confirm the suppression of IL-17 production by calpastatin,
we silenced the expression of the small subunit of calpain (CPNS),
a regulatory subunit of calpain, in CD4
+ T cells using an RNAi
approach. The knockdown of CPNS is known to reduce the large
subunit of both calpain I and II at the protein level and to interfere
Figure 3. Calpastatin-overexpression in Th cells resulted in decreased IL-6 and IL-17 production. (A) Naı ¨ve CD4
+ T cells were cultured
under neutral, Th1, Th2, or Th17 conditions. On day 1, these cells were infected with mock-GRV or calpain- or CS-dIV-GRV and expanded on day 2
with IL-2. On day 4 (Th17 conditions) or on day 6 (neutral, Th1, and Th2 conditions), the cells were restimulated with PMA/ionomycin for ICS.
Representative results for GFP
+-gated cells are shown (n=11 for IFNc, n=10 for IL-4, n=6 for IL-6 and IL-17). (B) Statistical analysis of the results in
panel A by Steel’s test. (C) Naı ¨ve CD4
+ T cells were cultured under neutral conditions and infected with mock-GRV or CS-dIV-GRV. On day 6, these cells
were restimulated with PMA/ionomycin for FACS. Representative data of GFP
+, GFP
2-gated cells are shown in the left panel, and the statistical
analysis is shown in the right panel (n=3) (D) Retrovirus-infected Th cells were stained with PKH-26 dye and then stimulated with anti-CD3/28
monoclonal antibodies. The fluorescence intensity of the PKH-26 dye in infected (GFP
+) and non-infected (GFP
2) cells was analyzed by FACS. *p,0.05
vs. mock.
doi:10.1371/journal.pone.0027020.g003
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but not complete depletion, of protein on day 7 after treatment
with the siRNA for CPNS probably because of the relatively long
half-life of calpain at the protein level (Figure 4A). We then
analyzed the IL-17 production under neutral conditions by ELISA
on day 7, and confirmed that the IL-17 production was suppressed
in Th cells treated with siRNA against CPNS (Figure 4B). We
supposed that calpain inhibition suppressed IL-17 production by
up-regulating the STAT5 signal via stabilization of the common
cytokine receptor gamma (cc) chain [40], because cytokine
signaling through the cc chain and STAT5 is critical for Th17
generation [41,42]. As shown in figure 4C, we confirmed that the
constitutive phosphorylation of STAT5 was up-regulated in the
CPNS-siRNA treated T cells, and not in control cells.
Overexpression of the minimal functional domain of
calpastatin suppresses NF-kB signaling by stabilizing IkBa
The molecular mechanism by which calpain inhibitors suppress
IL-6 production is reported to be the suppression of NF-kB
signaling by blocking calpain’s degradation of IkB [39,43,44,45].
However, it was not known whether the calpastatin minimum
functional domains have the same function as full-length
calpastatin. To test this mechanism, we first analyzed the NF-kB
signaling by electrophoresis mobility shift assay (EMSA) using
nuclear extracts from mock- and CS-dIV-overexpressing NIH-
3T3 cells. As shown in figure 5A, the CS-dIV-overexpressing
NIH-3T3 cells showed not only a suppressed peak of NF-kB
binding to the target sequence, but also a shorter duration of NF-
kB binding induced by LPS stimulation. We also confirmed that
the bands of NF-kB were specifically p65 by super shift assay. The
mean percent reduction in NF-kB binding at 1 hour after LPS
stimulation by CS-dIV overexpression was 58%, which was
statistically significant (Figure 5B). We next examined the
upstream signaling of NF-kB by western blot using cytoplasmic
extracts of the same cells. As shown in figure 5C, we confirmed
that there were no significant changes in upstream NF-kB
signaling events (the phosphorylation of p65 and IkBa) between
the mock- and CS-dIV-overexpressing NIH-3T3 cells.
We also observed an increase in the total IkBa protein in CS-
dIV-overexpressing NIH-3T3 cells at steady state (0 hours) and up
to 1 hour after LPS stimulation. To confirm the increase in total
IkBa protein in the CS-dIV-overexpressing NIH-3T3 cells more
precisely, we performed intracellular staining for IkBa, and
determined the mean fluorescence intensity (MFI) by flow
cytometry (Figure 5D–5E). We observed a significant increase in
IkBa-MFI (30%) in the CS-dIV-overexpressing NIH-3T3 cells.
These data confirmed that the overexpression of CS-dIV resulted
in increased IkBa and decreased NF-kB binding to its target DNA
in the nucleus, without decreasing their upstream signaling.
Overexpression of the minimal functional domain of
calpastatin suppresses IL-6 production in synovial
fibroblasts derived from RA patients
To confirm the anti-inflammatory effect of CS-dIV on primary
fibroblasts, we isolated synovial fibroblasts from RA patients and
infected these cells with mock- or CS-dIV-expressing retrovirus.
The infected cells were then sorted according to GFP expression
using FACS (purity .99%) (Figure 6A). These sorted cells were
then stimulated with LPS, and the IL-6 in the supernatant was
measured by ELISA. As shown in figure 6C, the overexpression of
CS-dIV suppressed not only the LPS-induced IL-6 production,
but also the basal production, completely. In addition, there was
no difference in the cell proliferation between the mock- and CS-
dIV-overexpressing synovial fibroblasts (Figure 6B). All of these
data suggested that the inhibition of calpain by a minimal
functional domain of calpastatin elicits a coordinated anti-
inflammatory effect by the inhibition of both IL-6 and IL-17
from not only T cells but also synovial fibroblasts.
Discussion
Calpain is known to be present in the synovial fluid of RA
patients [27,29,46] and in the arthritic joints of CIA mice [28].
Because calpain has proteoglycanase activity [29,47], it causes
cartilage damage in the joints of RA patients [28,46], and is
concomitantly involved in osteoclastic bone resorption [48]. In
addition, autoantibodies against calpastatin, a natural and specific
inhibitor of calpain, are widely observed in RA and psoriasis
patients [19,20,21], and positivity for anti-calpastatin antibodies is
known to correlate with serological markers of the disease activity
[23,24]. These findings strongly suggest that an insufficiency of
calpastatin or dominance of calpain contributes to the pathogen-
esis of inflammatory processes such as RA. In fact, we previously
Figure 4. Silencing of the calpain small subunit suppressed the
IL-17 production from Th cells. (A) Naı ¨ve CD4
+ T cells were cultured
under neutral conditions, and treated with siRNA against calpain small
subunit (CPNS). This experiment was carried out using two siRNAs
(CPNS1; C1 and CPNS2; C2). On day 3 and 7, these cells were lysed and
subjected to western blot analysis. NC; negative control. (B) On day 6,
the cells in panel A were washed 3 times and restimulated with an anti-
CD3 antibody for 48 hours. The culture supernatants were then
collected, and IL-17 was measured by ELISA. Statistical analysis of eight
independent experiments is shown (Steel’s test). (C) On day 6, the cells
in panel A were incubated with X-VIVO
TM 20 (without FCS) for the last
6 hours, then lysed and subjected to western blot analysis with the
indicated antibodies. Similar results were obtained in three indepen-
dent experiments. The band densities of pSTAT5 were measured and
normalized to that of total STAT5, then the percent change from NC
was calculated. Statistical analysis of three independent experiments is
shown in the right panel. *p,0.05 vs. NC.
doi:10.1371/journal.pone.0027020.g004
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Nuclear extracts from mock (M)- and CS-dIV (C)-overexpressing NIH-3T3 cells stimulated with LPS were subjected to EMSA. P, probe only; Co,
competition by preincubation with non-labeled probe; SS, super shift by preincubation with an anti-p65 antibody; NS, non-specific bands. Similar
results were obtained in six independent experiments. (B) Bands densities of NF-kB were measured and statistical analysis was performed. (C)
Cytoplasmic extracts from the same cells used in panel A were subjected to western blotting with the indicated antibodies. Similar results were
obtained in three independent experiments. (D) Mock- or CS-dIV-overexpressing NIH-3T3 cells were stained with IkBa antibodies intracellularly and
analyzed by flow cytometry. Similar results were obtained in six independent experiments. (E) Statistical analysis of the MFI of IkBa shown in panel C.
**p,0.01 vs. mock. endo-CS; endogenous calpastatin.
doi:10.1371/journal.pone.0027020.g005
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in CAIA mice via decreased IL-1b and IL-6 production in synovial
cells [33]. However, E-64-d is not a specific inhibitor of calpain; it
also inhibits cathepsins. Therefore, a more specific experimental
system for inhibiting calpain function was required to clarify its
effect on inflammatory cells. Moreover, little is known about the
effect of the calpain-calpastatin balance on Th cells.
In the present study, we established a system for overexpressing
calpastatin subdomains in primary cells and in cell lines, using a
retroviral expression system, and a CPNS knock-down system
using siRNA to achieve the specific loss of calpain function.
Notably, we generated a minimal functional domain of calpastatin
(CS-dIV) that was stably expressed in both cell lines and primary
cells, even though full-length calpastatin only showed short-term
expression. There might be some sequences in the full-length
calpastatin cDNA that are incompatible with the retrovirus vector,
or its length might simply be the problem. It is also possible that
the overexpression of full-length calpastatin has some toxic effects
on cells, while the minimal functional domain of calpastatin does
not. In fact, no toxicity was observed when CS-dIV was
overexpressed in either primary Th cells or fibroblasts. In any
case, these properties of CS-dIV were advantages for its use in
analyzing the gain of calpastatin function in vitro.
Using CS-dIV overexpression to obtain the specific loss of
calpain function in vitro, we demonstrated that it suppressed IL-6
production by reducing NF-kB signaling via the inhibition of IkBa
degradation, without affecting the upstream signals of NF-kB, in
NIH-3T3 cells. Several reports have shown that IkB is a substrate
Figure 6. Calpastatin overexpression in the synovial fibroblasts of RA patients efficiently suppressed IL-6 production. (A) Synovial
fibroblasts derived from RA patients were subjected to mock- or CS-dIV-GRV infection, and the infected cells were sorted by FACS. Sorting purity was
.99%. (B) The sorted GFP
+ cells in panel A were seeded into 96-well plates at 1000 cells/well. Forty-eight and 72 hours after seeding, ATP was
measured using a CellTiter-GloH Assay kit. Summarized data from three independent experiments are shown. (C) The cells used in panel B were
stimulated with the indicated concentration of LPS for 24 hours, and IL-6 in the culture supernatant was measured by ELISA. Similar results were
obtained in three independent experiments.
doi:10.1371/journal.pone.0027020.g006
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consequently reducing NF-kB signaling [44,45,49,50,51]. Because
all of these reports utilized calpain inhibitors that are not specific
for it, the results may include effects caused by inhibiting molecules
other than calpain. Although two other reports showed similar
findings using a calpastatin overexpression system, these were
performed in cell lines [39,43]. In the present study, we confirmed
that the overexpression of CS-dIV suppressed IL-6 production by
not only NIH-3T3 cells but also primary Th cells and fibroblasts
derived from the joints of RA patients. IL-6 is recognized as a
major proinflammatory cytokine responsible for the pathophysi-
ology of inflammatory diseases such as RA; the IL-6 level in
synovial fluids correlates with disease activity [52]. Moreover, an
anti-IL-6 receptor antibody suppresses RA in human patients
[53,54,55]. Notably, we found that the overexpression of CS-dIV
completely blocked the constitutive production of IL-6 from
inflammatory fibroblasts derived from RA patients. This result
supports the clinical application of directly overexpressing CS-dIV
in inflammatory sites such as the joints of RA patients.
NF-kB signaling is essential for IL-6 production, and IL-6 plays
a crucial role in IL-17 development [11]. Furthermore, NF-kBi s
known to be activated in the synovium of patients with RA
[56,57,58]. Therefore, the inhibition NF-kB signaling is a
promising strategy for controlling inflammatory diseases. Howev-
er, although many inhibitors to NF-kB are aggressively under
development, their specificity and toxicity are common problems
[59]. In the present study, we observed that only a moderate
increase in IkBa (+30%) had a relatively large impact on the
suppression of NF-kB signaling (258%) in NIH-3T3 cells. This
finding suggests that strategies such as increasing IkBa or
protecting it from degradation by calpain may efficiently inhibit
NF-kB. In fact, our results of CS-dIV overexpression in primary
fibroblasts derived from the joints of RA patients showed that CS-
dIV had a strong suppressive effect on the spontaneous production
of IL-6.
We next demonstrated that the inhibition of calpain activity by
overexpressing a minimal functional domain of calpastatin or by
CPNS-siRNA suppressed not only IL-6 but also IL-17 production
by Th cells. We supposed this effect resulted from the inhibition of
Th17 development via upregulation of the STAT5 signal, rather
than from the direct suppression of IL-17 expression. This scenario
is consistent with previous reports [40,41,42]. We also tested the
effect of calpain inhibition by CPNS-siRNA on other STAT
signals (STAT1, STAT4, and STAT6), and observed no obvious
changes (data not shown).
These data suggested that the calpain-calpastatin balance
specifically moderates STAT5 signaling, and suppresses Th17
development preferentially. Although Th17 cells are believed to
assume significant roles in inflammatory disease, controversy
remains over whether this is true in human RA [12,13,60]. To
address this issue, we and another group reported that the
synovial tissues and fluids of RA patients contain predominantly
IFN-c producing CD4
+ T cells, and that the emergence of Th17
cells is neither increased in RA nor correlated with disease
activity [14,15]. However, more recently, Leipe et al., using
samples from very early active and treatment-naı ¨ve RA patients,
reported that the percentage of Th17 cells correlates strongly
with the activity of RA, and concluded that Th17 cells play an
important role in human RA [61]. Furthermore, anti–IL-17A
antibodies (such as AIN457) are currently being investigated for
the clinical treatment of autoimmune diseases, including RA,
psoriasis, and Crohn’s disease, and therapeutic effects are
starting to be reported [62]. Therefore, the suppression of both
Th17 development and IL-6 production by T cells and non-T
cells, through overexpressing the calpastatin subdomain could be
a sophisticated strategy for treating inflammatory diseases such
as RA.
In conclusion, the inhibition of calpain function by calpastatin
overexpression suppresses Th17 development via an upregulation
of STAT5 signaling, and reduces IL-6 production via a repression
of NF-kB signaling in both T cells and non-T cells (for example,
synovial fibroblasts and macrophages). Not only does calpain have
immunological functions, but it also degrades the matrix
component of articular cartilage; therefore, the blockade of
calpain function could be a promising strategy for treating
inflammatory diseases such as RA. Because CS-dIV is a relatively
small polypeptide, coupling it with cell penetrating peptide (CPP)
will not be difficult. If CPP-coupled CS-dIV can be synthesized
efficiently, it will be a novel candidate for the therapeutic control
of RA-associated joint inflammation, because it can be injected
locally and will penetrate inflammatory cells, in which it will
function as both an NF-kB and an IL-17 inhibitor, without the risk
of systemic effects.
Supporting Information
Figure S1 The expressions of calpastatin and calpain
under neutral conditions in Th cells over time. Naı ¨ve
CD4
+ T cells were cultured under neutral conditions, and the
lysates were subjected to western blot analysis with the indicated
antibodies. Data are representative of three independent experi-
ments.
(TIF)
Figure S2 Retrovirally transfected proteins in naı ¨ve T
cells over time. Naı ¨ve CD4
+ T cells obtained from the
splenocytes of BALB/c mice were infected with mock-, calpasta-
tin-, calpain-, or modified calpastatin-GRV, and the infection
efficiency was determined from the GFP expression using flow
cytometry. Data are representative of seven independent exper-
iments.
(TIF)
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